8. Lu D, Pavlakis SG, Frank Y et al Proton MR spectroscopy of the basal ganglia in healthy children and children with AIDS. Radiology 1996; 199: 423-28 Planning trials in older patients with stroke: data from the International Stroke Trial SIR-Older people have been substantially underrepresented in randomised trials of treatments for acute stroke and stroke prevention, so there is a need to gather good quality evidence from randomised trials on the effects of treatments in older people [1, 2] . We aimed to demonstrate that it is feasible to perform trials which recruit large numbers of very old stroke patients [3] and to describe the frequency of important outcomes in a cohort of patients with acute ischaemic stroke aged over 80, as an aid to planning future studies which seek to include older stroke subjects.
Planning trials in older patients with stroke: data from the International Stroke Trial SIR-Older people have been substantially underrepresented in randomised trials of treatments for acute stroke and stroke prevention, so there is a need to gather good quality evidence from randomised trials on the effects of treatments in older people [1, 2] .
We aimed to demonstrate that it is feasible to perform trials which recruit large numbers of very old stroke patients [3] and to describe the frequency of important outcomes in a cohort of patients with acute ischaemic stroke aged over 80, as an aid to planning future studies which seek to include older stroke subjects.
Methods
The methods used in International Stroke Trial (IST) have been described in detail elsewhere, but briefly 19,435 patients were randomised, in whom the final diagnosis was a confirmed ischaemic stroke in 17,370, clinically definite stroke of unknown pathological type in 992 and haemorrhagic stroke in 599 patients [3] . We present data for those with confirmed ischaemic stroke.
We chose 'over 80 years at stroke onset' as our definition of 'oldest old' as this cut-off had been used in a number of earlier publications on the topic and in several randomised trials of treatments for acute stroke and for stroke prevention [4] [5] [6] [7] [8] [9] [10] .
We extracted the baseline data and the frequency of outcome events within 14 days and final outcome at 6 months.
Sources of funding
Details of the funding sources for IST were given in the main publication [3] .
Belgium. The characteristics of patients at randomisation are given in Table 1 . Patients aged 80 or more were more often female, with impaired consciousness and with the most severe stroke subtype-total anterior circulation stroke (TACS). Older patients had twice the frequency of atrial fibrillation (AF) at baseline than younger stroke patients. There was no significant difference in systolic BP level, mean time from onset to randomisation and the use of aspirin in the 3 days before stroke onset.
Events within 14 days
Patients aged over 80 had a higher case fatality, with a higher proportion of deaths attributed to the deficit from the initial stroke (Table 2) .
At 6 months from onset
Older people were less likely to be on antiplatelet drugs (72.1 versus 76.5%) or anticoagulants (9.4 versus 13.8%). The older patients were significantly more likely to be either dead or dependent. Complete recovery was less common in those older than 80 years (19.7 versus 26.3%). Among older patients, deaths within 6 months were more commonly attributed to the initial stroke, recurrent stroke, pneumonia and other vascular causes. Older patients were less likely to be discharged to their own home and more likely to be discharged to residential home, nursing home or other hospital departments ( Table 2 ).
Discussion
The broad entry criteria, and the lack of an upper age limit employed (the 'uncertainty principle' advocated by Peto and Baigent [11] ) facilitated the recruitment of a substantial number of older patients in IST.
The estimates of the event rates are precise as they were derived from the largest ever (to our knowledge) cohort of patients of this age to be recruited in an RCT with acute stroke, within 48 h of onset. This precision increases their value for planning future trials. Follow-up was virtually complete. However, the patients were recruited between 1992 and 1996, at the time when stroke unit care was not widely prevalent and background medical therapy was limited. Thrombolytic therapy was not available in almost all of the hospitals. These data are likely to have greatest relevance therefore for planning trials in resource-poor settings where stroke unit care is infrequent or not-existent.
To facilitate trial planning (including more advanced sample size calculations based on time-to-event data), we have created an open-access version of the full data set (see http ://datashare.is.ed.ac.uk/). A review of studies in acute stroke showed that, compared with younger patients, the very old have much higher early case-fatality and poorer long-term outcome ( please see Table S1 in Appendix 1, Supplementary data are available in Age and Ageing online). There is relatively little information about the nature and outcome of stroke and the effect of treatment in very old persons [1, 2, 12] . For example, for rt-PA, most of the trials (ATLANTIS [7] , ECASS I [8] , II [9] and III [10] ) explicitly excluded patients aged over 80 years old. Only one thrombolysis study (NINDS) did not set an upper age limit for study inclusion, so the total number of patients aged over 80 in randomised trials of rt-PA is just 67 [13, 14] . As a result the EU approval for rt-PA in ischaemic stroke treatment is restricted to patients younger than 80. However, many older patients are biologically youthful and have had active lives before their acute stroke. There remains a need for randomised trial evidence of the effect of treatments, such as thrombolytic therapy, in stroke patients aged over 80. The Third International Stroke Trial (IST-3) will provide such data (www.ist3.com); it has no upper age limit [15] and by 31.12.10 had recruited 2,624 patients, of whom over 1,200 were aged >80 (IST3 group, personal communication).
In IST, people aged over 80 years had more severe strokes and therefore a worse outcome, confirming other studies [5, 16, 17] . This will be partially related to the higher prevalence of atrial fibrillation, and subsequently more cardioembolic stroke, with partial anterior cirulation stroke (PACS) and TACS subtype [18, 19] .
The deaths among older patients were more often attributed to the effects of the initial stroke, and to cardiac and respiratory complications than to other causes. As the risks of poor outcome were far greater in older people, they may have more to gain from interventions such as thrombolysis, even if the risks of such treatments also increase with age. Foerch et al. have called for trials in older people [20] so we hope these data, among patients aged over 80, not treated with thrombolysis, may provide useful background data that will assist in planning of such trials. At least one of thrombolysis restricted in patients over 80 is under way [21] and IST-3 is actively recruiting such patients. Finally, we hope that future trials, including those of medical and surgical interventions for haemorrhagic stroke (whose incidence of rises steeply with age), and trials of stroke therapy in the developing world will not impose upper age limits.
Key points
• Older people, especially those over 80, are underrepresented in trials of stroke treatment and prevention.
• New trials are needed which include a significant proportion of older people.
• To facilitate the planning of trials, we report the frequency of outcomes among the acute ischaemic stroke patients aged over 80.
• At baseline patients aged over 80 years more often had impaired consciousness, severe stroke (TACS), atrial fibrillation.
• Fourteen-days fatalities of patients over 80 were more often attributed to the neurological deficit resulting from the initial stroke.
Supplementary data
Supplementary data mentioned in the text is available to subscribers in Age and Ageing online. 
